With ardent vigor and unwavering dedication, the past year has seen significant advances in the field of hematologic oncology, driven by the rapid development of innovative therapies and cutting-edge technologies. The application of novel molecular biology techniques has not only refined the prognostic stratification of Acute Myeloid Leukemia (AML) but has also fostered more precise diagnostics and treatments. At the turn of the year, Oncology Frontier - Hematology Frontier has invited Professor Hui Wei, Director of the Leukemia Diagnosis and Treatment Center at the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, to review the latest advancements in the precise diagnosis and treatment of AML in 2023, and to look forward to the future prospects and directions of AML treatment.

From January 26 to 28, 2024, the "Chinese Society of Clinical Oncology (CSCO) Leukemia Committee, Lymphoma Committee, and Myeloma Preparatory Committee Work Meeting and 2024 CSCO Blood, Lymphoma, and Myeloma Diseases Academic Conference" was held in Haikou. Many authoritative hematologists from home and abroad gathered to share their insights. Professor LanPing Xu from the Hematology Institute of Peking University People's Hospital delivered an in-depth lecture on the topic of "Hematopoietic Stem Cell Transplantation for the Treatment of Severe Aplastic Anemia (SAA)," providing rich and fascinating content, summarized by "Oncology Outlook-Blood News."